康华生物疫苗扩建项目进度调整 项目核心建设已完成

Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. has announced a prudent adjustment to the implementation schedule of its fundraising project "Vaccine Production Expansion Project," moving the expected completion date from December 31, 2025, to June 30, 2026 [1][2] Group 1: Project Adjustment Details - The adjustment only involves the project timeline and does not change the implementation entity, location, or the use of raised funds [1] - The project has completed workshop construction, equipment debugging, trial production, drug registration site inspection, GMP compliance checks, and is currently in the supplementary application review stage [1] Group 2: Regulatory and Management Insights - The adjustment is not due to project obstacles but is a necessary coordination with regulatory processes [2] - The company aims to ensure that the project operates in a fully compliant and stable manner by dynamically optimizing expectations based on actual approval rhythms [2] Group 3: Strategic Importance - The expansion project is a strategic move for Kanghua Biological to solidify core production capacity and align with future market demands [2] - Despite the short-term schedule adjustment, the completion of the main engineering and the most challenging review stages has not affected the long-term strategic value and potential contribution to performance [2]